


IN THE SPECIFICATION

At page 1, before the heading "DESCRIPTION", please insert the following new paragraph:

[0000] This application is a U.S. national stage filing under 35 U.S.C. §371 of International Application No. PCT/EP2004/008169 filed on July 22, 2004, which claims priority of German Application No. DE 103 34 187.0 filed on July 26, 2003. This application contains subject matter that is related to a concurrently filed U.S. Application by the same applicants titled "Use of rotigotine for the treatment of depression" (Serial No. not yet assigned). The disclosure of each of the applications identified in this paragraph is incorporated herein by reference in its entirety.

Please replace paragraphs [0003] and [0004] with the following replacement paragraphs:


[0003] It has now been surprisingly found that said substituted 2-aminotetralins of the general formula I



wherein:

n is 1-5;


R2 is OA; R3 and R4 are each independently selected from H and OA; with A being selected from H, C1-3 alkyl or a group



wherein R6 and R7 are each independently alkyl, in particular C1-20 alkyl, or aryl, in particular optionally substituted phenyl;

R5 is a C1-3 alkyl;

R1 is a group selected from hydrogen, 3-pyridyl, 4-pyridyl, optionally substituted phenyl, or a group




wherein X is selected from S, O or NH;

and wherein the compound of formula I can be present as racemate or as a pure (R)- or (S)-enantiomer,

as well as physiologically acceptable salts of these compounds, are useful in a method for treating depression in a mammal, comprising administering a therapeutically effective amount thereof to the mammal, and are suitable for the production of medicaments for the treatment of depression.

**[0004]** Compounds that are particularly useful in such a method and particularly suitable for the production of an antidepressant are those in which R<sub>2</sub> is an OA group and R<sub>3</sub> and R<sub>4</sub> are independently H or an OA group, it being particularly preferred for A to be selected from a hydrogen atom or a group



in which R<sub>6</sub> is a C<sub>1</sub>-20 alkyl, in particular C<sub>1</sub>-12 alkyl, phenyl or methoxyphenyl.

Please replace paragraph **[0013]** with the following replacement paragraph:

**[0013]** In a particularly preferred embodiment of the invention, the racemate of (+/-) 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol, and especially preferred the pure S-enantiomer of this compound (rotigotine), is used in the method for treating depression in a mammal, or for the production of the medicament for the treatment of depression.

Please replace paragraph **[0018]** with the following replacement paragraph:

**[0018]** In a further animal model (embodiment 3), it was examined whether the antidepressive effects of rotigotine can be distinguished from a general motor stimulation. In this case, rotigotine was administered to rats whose olfactory bulbs had been removed

on both sides. The removal of the olfactory bulb leads to an adaptive hyperactivity in the untreated control group. It is known from literature that chronically administered antidepressants lead to a reduction in the movement activity of the animals in this model, whereas stimulants further increase the motor activity (van Riezen H *et al*, Br J Pharmacol. 60(4), 1977, 521; Kelly JP *et al*, Pharmacol Ther. 74(3), 1997, 299). Therefore, it is possible to discriminate between antidepressive and non-specific stimulatory effects of an active ingredient with this model. It has now been shown that rotigotine exhibits a specifically antidepressive effect in low doses, which approximately corresponds to the effect of the antidepressant imipramine and which leads to almost complete suppression of the bulbectomy-induced locomotor hyperactivity. In the case of higher rotigotine concentrations on the other hand, the stimulatory dopamine-agonistic effect is dominant.

Please replace paragraph [0024] with the following replacement paragraph:

**[0024]** A subject matter of the invention is therefore the use of compounds of formula I, in particular rotigotine, as well as salts of these compounds for the production of a medicament for the treatment of depression; and a method for treating depression in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of formula I, in particular rotigotine, or a salt of such a compound.

Please replace paragraphs [0029] and [0030] with the following replacement paragraphs:

**[0029]** Compounds of formula I, in particular rotigotine, as well as the salts thereof are basically suitable for ~~the production of a medicament~~ administering to a mammal for [[the]] treatment of the various forms of depression mentioned above or for [[the]] treatment of affective disorders, in particular depressive episodes, recurrent depressive disorders, cyclothymia and depressive phases in bipolar affective disorders, according to ICD-10.

**[0030]** According to the invention, compounds of formula I are preferably used for ~~the production of a medicament for the~~ treatment of depressive episodes and serious recurrent depressive disorders such as those occurring, for example, in the case of endogenous, unipolar depression ("major depression").

Please replace paragraphs [0033] and [0034] with the following replacement

paragraphs:

[0033] The compounds of formula I, in particular rotigotine, and the salts thereof are also particularly suitable for ~~the production of antidepressants for the~~ treatment of depressive episodes in manic-depressive patients. In this patent application, these depressive phases in bipolar disorders are subsumed under the term “depression”.

[0034] Furthermore, the compounds of formula I are preferably used for ~~the production of a medicament for the~~ treatment of “organic” depression which is described above. Organic depression often occurs, for example, in Parkinson’s disease or in cerebrovascular diseases and in dementia disorders.

Please replace paragraphs [0036] and [0037] with the following replacement paragraphs:

[0036] A subject matter of the invention is therefore the use of compounds of formula I, in particular rotigotine, and salts of these compounds for the production of a medicament for the treatment of depression linked with Parkinson’s disease; and a method for treating depression linked with Parkinson’s disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of formula I, in particular rotigotine, or a salt of such a compound, whereby co-medication with other antidepressants can be optionally forgone.

[0037] Another subject matter of the invention is the use of compounds of formula I, in particular rotigotine, as well as salts of these compounds, in each case alone or in combination with other antidepressants, for the treatment of organic depression which is not linked with Parkinson’s disease; and a method for treating organic depression not linked with Parkinson’s disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of formula I, in particular rotigotine, or a salt of such a compound, alone or in combination with another antidepressant. Examples of such organic depression include depression associated with brain tumours, migraines, epilepsy, brain paralysis, brain arteriosclerosis, brain traumas, meningitis, strokes, dementia, Alzheimer’s disease or Parkinson Plus Syndrome.